ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

National Trends in Locoregional Therapy among Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) in the United States

A. Kwong1, W. Kim1, F. Yao2, N. Mehta2

1Stanford University, Redwood City, CA, 2University of California, San Francisco, San Francisco, CA

Meeting: 2020 American Transplant Congress

Abstract number: 147

Keywords: Hepatocellular carcinoma, Liver, Liver transplantation, Waiting lists

Session Information

Session Name: Liver: Hepatocellular Carcinoma and Other Malignancies I

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:51pm-4:03pm

Location: Virtual

*Purpose: Advances in locoregional therapy (LRT) have expanded treatment options for patients with HCC. As recent policy changes in the United States (US) have lengthened waiting times for patients with HCC, an increasing proportion receive LRT as bridging therapy prior to LT. The aim of this study was to investigate temporal trends in LRT among LT candidates in the US.

*Methods: Data for all primary adult LT candidates listed from 2003 and 2018 who received an HCC exception were extracted from the national US registry. The date and type of LRT, if any, was reported with each submitted HCC exception application. Combination therapy (i.e. ablation + chemoembolization or radioembolization) was defined as receipt of these therapies within 30 days. Linear regression models were used to evaluate variables that were associated with greater number of treatments. Multivariable Cox regression analysis was used to evaluate the association between type of LRT and waitlist dropout, defined by removal from the list for death or being too sick.

*Results: There were 31,464 eligible patients with at least one approved HCC exception application. In total, there were 34,445 treatments among 24,031 LT candidates. The proportion of patients with at least one LRT recorded increased from 42.1% in 2003 to 92.0% in 2018. Figure 1 demonstrates trends in number of treatments per patient by year of listing, and treatment type based on the year of treatment. Chemoembolization remains the most frequent type of LRT, followed by ablation. However, there has been a notable increase in radioembolization in the past 5 years, now making up 19% of LRT in 2018, compared to <5% as recently as 2013. Initial HCC outside T2 criteria, AFP > 500, Child-Pugh class A, lower MELD, and listing in longer wait time regions was associated with a greater number of liver-directed treatments while awaiting LT (p<0.05 for all). In the multivariable Cox regression analysis, adjusting for AFP, Child-Pugh class, MELD, wait time region, and year of listing, receipt of LRT was associated with a lower risk of waitlist dropout, including chemoembolization (HR 0.85), ablation (HR 0.74), external beam radiation (HR 0.62), and radioembolization (HR 0.85) (p<0.05 for all).

*Conclusions: In the US, LRT — and in particular radioembolization — is increasingly used to bridge to LT. Patients with HCC outside T2 criteria and those with more compensated liver disease undergo more treatments while awaiting LT. Receipt of LRT is associated with a lower risk of waitlist dropout.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kwong A, Kim W, Yao F, Mehta N. National Trends in Locoregional Therapy among Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) in the United States [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/national-trends-in-locoregional-therapy-among-liver-transplant-lt-candidates-with-hepatocellular-carcinoma-hcc-in-the-united-states/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences